cabozantinib,atezolizumab
roche
['contact 03', 'cabo ', 'rcc,(-irccs),(-srcc),(-urcc)', 'atezo']
io post io . no benifit in mrcc . contact 03 study. atezo plus cabo vs cabo . for second line. post io . we need better strategy to treat these pts . #asco23 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists